Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Drug Discovery Outsourcing Market, By Workflow
7.1. Drug Discovery Outsourcing Market, By Workflow Type, 2020-2030
7.1.1. Target Identification & Screening
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Target Validation & Functional Informatics
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Lead Identification & Candidate Optimization
7.1.3.1. Market Revenue and Forecast (2016-2030)
7.1.4. Preclinical Development
7.1.4.1. Market Revenue and Forecast (2016-2030)
7.1.5. Other Associated Workflow
7.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Drug Discovery Outsourcing Market, By Therapeutics Area
8.1. Drug Discovery Outsourcing Market, By Therapeutics Area, 2020-2030
8.1.1. Respiratory System
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Pain & Anesthesia
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Oncology
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Ophthalmology
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Hematology
8.1.5.1. Market Revenue and Forecast (2016-2030)
8.1.6. Cardiovascular
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Immunomodulation
8.1.7.1. Market Revenue and Forecast (2016-2030)
8.1.8. Anti-Infective
8.1.8.1. Market Revenue and Forecast (2016-2030)
8.1.9. Central Nervous System
8.1.9.1. Market Revenue and Forecast (2016-2030)
8.1.10. Dermatology
8.1.10.1. Market Revenue and Forecast (2016-2030)
8.1.11. Genitourinary System
8.1.11.1. Market Revenue and Forecast (2016-2030)
8.1.12. Endocrine
8.1.12.1. Market Revenue and Forecast (2016-2030)
8.1.13. Gastrointestinal
8.1.13.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Drug Discovery Outsourcing Market, By Drug Type
9.1. Drug Discovery Outsourcing Market, By Drug Type, 2020-2030
9.1.1. Small Molecules
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Large Molecules (Biopharmaceuticals)
9.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.1.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.1.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.1.4.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.1.4.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.1.5.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.1.5.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.2.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.2.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.2.4.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.2.4.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.2.5.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.2.5.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.2.6.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.2.6.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.2.7.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.2.7.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.3.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.3.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.3.4.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.3.4.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.3.5.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.3.5.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.3.6.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.3.6.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.3.7.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.3.7.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.4.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.4.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.4.4.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.4.4.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.4.5.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.4.5.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.4.6.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.4.6.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.4.7.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.4.7.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.5.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.5.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.5.4.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.5.4.3. Market Revenue and Forecast, By Drug Type (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, By Workflow (2016-2030)
10.5.5.2. Market Revenue and Forecast, By Therapeutics Area (2016-2030)
10.5.5.3. Market Revenue and Forecast, By Drug Type (2016-2030)
Chapter 11. Company Profiles
11.1. Albany Molecular Research Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. EVOTEC
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Laboratory Corporation of America Holdings
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. GenScript
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Pharmaceutical Product Development, LLC
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Charles River
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. WuXi AppTec
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Merck & Co., Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Thermo Fisher Scientific Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Dalton Pharma Services
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Oncodesign
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Jubilant Biosys
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. DiscoverX Corporation
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. QIAGEN
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms